The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Renal Cell Carcinoma News
RENAL CELL CARCINOMA ADVISOR
Renal Cell Carcinoma News
Intermediate-Risk mRCC Patients Have Heterogeneous Survival Outcomes
Survival of patients with intermediate-risk metastatic renal cell carcinoma varied according to the number of IMDC or MSKCC risk factors.
Ipilimumab Plus Nivolumab Effective for mRCC With Brain Metastases
Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.
Metastasectomy Found to Prolong Survival in Selected mRCC Cases
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
CN for mRCC Does Not Up Survival in the Immune Checkpoint Inhibitor Era
In a study, cytoreductive nephrectomy was not independently associated with improved survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitors.
Immune Checkpoint Inhibitors for mRCC Safe, Effective in a Real-World Setting
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
Preoperative Bone Metastases Not Prognostic in mRCC
Bone metastases less predictive in the setting of cytoreductive nephrectomy.
Nivolumab Outperforms Everolimus in Advanced RCC, Study Confirms
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Risky Business: A New Scoring System for Metastatic Renal Cell Carcinoma
The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.
Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
Kidney Cancer Risk Tied to Body Size in Early Life
Higher birth weight and overweight in childhood found to predict an increased risk of renal cell carcinoma in adulthood, a large Danish study found.
The Unexpected Costs of Cancer Treatment: Out-of-Network Billing
The cancer field is not immune to the challenges of out-of-network and surprise billing.
Renal Function After RCC Surgery May Impact Cancer-Specific Survival
Better renal function preservation is associated with decreased cancer-specific death risk among patients who have an estimated glomerular filtration rate (eGFR) below 85 mL/min/1.73 m2 after surgery for organ-confined renal cell carcinoma, a study found.
Tivozanib Shows Superior Safety Profile Across TKIs in Metastatic Renal Cell Carcinoma
For the study, researchers conducted a literature review and network meta-analysis of phase 2/3 randomized controlled trials of approved first-line TKI therapies for mRCC.
Open Radical Nephrectomy for RCC May Increase Circulating Tumor Cells
The investigators observed significantly higher postoperative CTC counts in the open radical nephrectomy group compared with the other 3 groups in the study.
Bevacizumab Adoption Tied to Use by Peers
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
Want to read more?
Please login or register first to view this content.
